Sanctuary Advisors LLC Invests $202,000 in Blueprint Medicines Co. (NASDAQ:BPMC)

Sanctuary Advisors LLC acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,144 shares of the biotechnology company’s stock, valued at approximately $202,000.

A number of other large investors have also made changes to their positions in BPMC. Raymond James & Associates boosted its position in Blueprint Medicines by 45.2% during the 2nd quarter. Raymond James & Associates now owns 13,550 shares of the biotechnology company’s stock worth $1,460,000 after acquiring an additional 4,215 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Blueprint Medicines by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 273,930 shares of the biotechnology company’s stock worth $29,524,000 after buying an additional 32,740 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Blueprint Medicines by 8.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,792 shares of the biotechnology company’s stock valued at $1,487,000 after acquiring an additional 1,064 shares during the period. Crossmark Global Holdings Inc. bought a new stake in shares of Blueprint Medicines in the 2nd quarter valued at about $381,000. Finally, Van ECK Associates Corp increased its position in Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after buying an additional 131 shares during the last quarter.

Blueprint Medicines Trading Down 2.4 %

NASDAQ BPMC opened at $89.40 on Monday. The stock’s 50-day simple moving average is $92.74 and its two-hundred day simple moving average is $96.60. The company has a market capitalization of $5.68 billion, a price-to-earnings ratio of -42.37 and a beta of 0.59. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company’s quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.20) earnings per share. Research analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the sale, the insider now directly owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total value of $218,099.34. Following the completion of the transaction, the chief operating officer now owns 69,383 shares in the company, valued at approximately $6,654,523.53. This trade represents a 3.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,353 shares of company stock valued at $2,502,346 over the last ninety days. 4.21% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BPMC. Needham & Company LLC reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a research report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price target on the stock. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Monday, December 9th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $123.33.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.